137 related articles for article (PubMed ID: 15860667)
1. Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis.
Han SY; Lee NK; Kim KH; Jang IW; Yim M; Kim JH; Lee WJ; Lee SY
Blood; 2005 Aug; 106(4):1240-5. PubMed ID: 15860667
[TBL] [Abstract][Full Text] [Related]
2. Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation.
Liu Y; Shi Z; Silveira A; Liu J; Sawadogo M; Yang H; Feng X
J Biol Chem; 2003 Jun; 278(23):20603-11. PubMed ID: 12663664
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
4. IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage.
Khapli SM; Mangashetti LS; Yogesha SD; Wani MR
J Immunol; 2003 Jul; 171(1):142-51. PubMed ID: 12816992
[TBL] [Abstract][Full Text] [Related]
5. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism.
Gruber R; Karreth F; Fischer MB; Watzek G
Bone; 2002 May; 30(5):726-32. PubMed ID: 11996911
[TBL] [Abstract][Full Text] [Related]
6. SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL.
Tsujisawa T; Inoue H; Nishihara T
J Bone Miner Res; 2005 Jan; 20(1):15-22. PubMed ID: 15619665
[TBL] [Abstract][Full Text] [Related]
7. Periodontal ligament cells under mechanical stress induce osteoclastogenesis by receptor activator of nuclear factor kappaB ligand up-regulation via prostaglandin E2 synthesis.
Kanzaki H; Chiba M; Shimizu Y; Mitani H
J Bone Miner Res; 2002 Feb; 17(2):210-20. PubMed ID: 11811551
[TBL] [Abstract][Full Text] [Related]
8. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
9. Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles.
Wei X; Zhang X; Zuscik MJ; Drissi MH; Schwarz EM; O'Keefe RJ
J Bone Miner Res; 2005 Jul; 20(7):1136-48. PubMed ID: 15940366
[TBL] [Abstract][Full Text] [Related]
10. YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation.
Shi Z; Silveira A; Patel P; Feng X
Gene; 2004 Dec; 343(1):117-26. PubMed ID: 15563837
[TBL] [Abstract][Full Text] [Related]
11. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
[TBL] [Abstract][Full Text] [Related]
12. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis.
Bharti AC; Takada Y; Aggarwal BB
J Immunol; 2004 May; 172(10):5940-7. PubMed ID: 15128775
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency.
Kanematsu M; Sato T; Takai H; Watanabe K; Ikeda K; Yamada Y
J Bone Miner Res; 2000 Jul; 15(7):1321-9. PubMed ID: 10893680
[TBL] [Abstract][Full Text] [Related]
14. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
16. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
17. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
18. TNF-alpha expression is transcriptionally regulated by RANK ligand.
Zou W; Amcheslavsky A; Takeshita S; Drissi H; Bar-Shavit Z
J Cell Physiol; 2005 Feb; 202(2):371-8. PubMed ID: 15389596
[TBL] [Abstract][Full Text] [Related]
19. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
20. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor.
Huber DM; Bendixen AC; Pathrose P; Srivastava S; Dienger KM; Shevde NK; Pike JW
Endocrinology; 2001 Sep; 142(9):3800-8. PubMed ID: 11517156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]